Skip to main content
. 2022 Mar 15;33(3):200–206. doi: 10.1097/DER.0000000000000845

Figure 1.

Figure 1

Study selection for the scoping review on the treatment of AD in people with HIV, viral hepatitis B or C, liver disease, renal disease, or a history of malignancy.